CDC Activates Level 1 Response to DRC Ebola Outbreak Sending MBP134 Doses

US authorities declared the internal Level 1 activation to prioritize staffing and resources, matching the 2014 West Africa epidemic scale. Officials simultaneously shipped experimental monoclonal antibody MBP134 to the DRC and Uganda while preparing 2,500 post-mortem diagnostic tests. The Bundibugyo strain lacks approved vaccines, distinguishing this event from prior Zaire-strain responses.

The outbreak reached Uganda with 20 confirmed cases and two deaths since 15 May. Containment there has so far limited further spread, yet officials note the 2014-2016 epidemic killed more than 11,000 after originating in Guinea. Current case counts remain far below that total but trajectory warnings cite risks of exponential growth without rapid intervention.

Observational surveillance data from DRC and Uganda ministries, triangulated with CDC assessments, show consistent reporting delays typical of conflict-affected regions. No randomized data yet exist on MBP134 efficacy against Bundibugyo; the Oxford trial shipment represents the first controlled evaluation. Historical patterns indicate early ring-vaccination analogs reduced transmission only after 60-70 percent coverage.

Next steps hinge on whether case incidence exceeds 50 new infections per week in the next 30 days. Expanded genomic sequencing and contact-tracing coverage will determine if Level 1 mobilization alters the outbreak curve before the 2026 rainy season begins.